Korean Circ J.  2020 Nov;50(11):995-997. 10.4070/kcj.2020.0398.

Renin-Angiotensin System Blockade in Acute Myocardial Infarction: Is There a Winner?

• Lee HS
• Kang Jh

• KMID: 2508278
• DOI: http://doi.org/10.4070/kcj.2020.0398

Reference

1. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995; 345:669–685. PMID: 7661937.

2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39:119–177. PMID: 28886621.

3. Kim I, Park CS, Lee HY. Angiotensin II type 1 receptor blocker, fimasartan, reduces vascular smooth muscle cell senescence by inhibiting the CYR61 signaling pathway. Korean Circ J. 2019; 49:615–626. PMID: 31074217.

4. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006; 114:838–854. PMID: 16923768.

5. Gayet JL. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. The OPTIMAAL trial: losartan or captopril after acute myocardial infarction. Lancet. 2002; 360:1884–1885.

6. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349:1893–1906. PMID: 14610160.

7. Won H, Suh Y, Kim GS, Ko YG, Hong MK. Clinical impact of beta blockers in patients with myocardial infarction from the Korean National Health Insurance Database. Korean Circ J. 2020; 50:499–508. PMID: 32096355.

8. Kim GS, Ko YG, Suh Y, et al. Impact of angiotensin II receptor blockers on clinical outcomes after percutaneous coronary intervention in patients with acute myocardial infarction based on data from the Korean National Health Insurance Database (2005–2014). Korean Circ J. 2020; 50:984–994. PMID: 32725998.

9. Hall AS, Strauss MH. More about the “ARB MI paradox”. Heart. 2007; 93:1011–1014. PMID: 17699164.

10. Mogensen UM, Køber L, Kristensen SL, et al. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J. 2017; 188:35–41. PMID: 28577679.